CIPLA TO MANUFACTURE ANTI-INFECTIVE FOR AKORN
Indian-based pharmaceutical company Cipla has entered into an agreement to manufacture
and supply an oral anti-infective drug product to US-based Akorn. Under the
terms of the ten-year agreement, Cipla will be responsible for the manufacturing
and supply of the drug using Akorn's formulation, and Akorn will be responsible
for the abbreviated new drug application (ANDA) regulatory submission and clinical
development, and for the purchase of specialized manufacturing equipment.
Pharmaceutical Business Review